Biopharmaceutical Dealmaking Exhibit 2
Top Ten Pharmaceutical Acquisitions Of 2010*
Acquirer
Acquired
Primary assets gained through the deal
March
Teva
ratiopharm
Significant share of the European generics market
4,989
June
Grifols
Talecris
Plasma-derived therapeutics
4,000
July
Reckitt Benckiser
SSL International
Personal care products, plus opportunities for expansion into Asia
3,961
June
BASF
Cognis
Specialty chemicals, dietary supplements, APIs , and drug delivery agents
3,823
May
Abbott
Piramal
350 branded generics; the deal makes Abbott the largest drug producer in India
3,720
Oct.
Pfizer
King
Specialty pharmaceuticals with a focus on pain management
3,561
June
Celgene
Abraxis
Cancer drug Abraxane (paclitaxel formulation) and nab nanoparticle delivery technology
March
Astellas
OSI
EGFR inhibitor Tarceva for pancreatic and non-small cell lung cancers; oncology pipeline
3,519
June
Valeant
Biovail (reverse merger – Biovail has a 50.5% stake in the combined company, which keeps the Valeant name)
Neurology and dermatology drugs and expanded presence in North America and emerging markets
3,272
Sept.
Johnson & Johnson
Crucell
Infectious disease vaccines and monoclonal antibodies; the deal makes J&J the sixth-largest vaccines producer
2,167
Those highlighted were nominees for IN VIVO Blog’s 2010 Deal of the Year. *List includes biopharma and OTC/personal care companies; excludes Research/Analytical companies. SOURCE: Elsevier’s Strategic Transactions
8
Potential Deal Value ($ millions)
Date
| January 2011 | IN VIVO: The Business & Medicine Report | www.ElsevierBI.com
3,559 (consists of $2.9bn in cash and Celgene stock, plus $650mm in tradable CVRs tied to Abraxane)